Anita Kumar
Associate Attending
Memorial Sloan Kettering Cancer Center · New York, United States
MCL specialist at Memorial Sloan Kettering focused on optimizing frontline treatment strategies and MRD-guided approaches.
Unusual Skeletal Muscle Recurrence of Mantle Cell Lymphoma After Rituximab Maintenance Therapy Detected on 18 F-FDG PET/CT.
Clinical nuclear medicine · May 1, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
Blood advances · Feb 24, 2026
Gastric Lymphoma
Asia Oceania journal of nuclear medicine & biology · Jan 1, 2026
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.
Haematologica · Nov 27, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.
Blood advances · Nov 11, 2025
Correlation between TP53 mutational status and digital quantification of p53 immunohistochemistry in mantle cell lymphoma.
Virchows Archiv : an international journal of pathology · Sep 1, 2025
Leukemic presentation in nodal mantle cell lymphoma is characterized by frequent SOX11 negativity, a poor risk genomic landscape including higher TP53 alterations, and worse overall survival.
Haematologica · Sep 1, 2025
Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 10, 2025
Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma.
British journal of haematology · Jun 23, 2025
Multisite clinical cross-validation and variant interpretation of a next generation sequencing panel for lymphoid cancer prognostication.
Journal of clinical pathology · Feb 18, 2025
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Blood · Jan 30, 2025
Ibrutinib-Related Uveitis: A Case Series from Two Tertiary Centres in the United Kingdom.
Ocular immunology and inflammation · Dec 1, 2024
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.
Leukemia & lymphoma · Dec 1, 2024
Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma.
Leukemia · Oct 1, 2024
Dismantling relapsed/refractory mantle cell lymphoma.
Blood reviews · Sep 1, 2024
Correction: Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma.
Leukemia · Sep 1, 2024
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression.
Blood advances · Aug 27, 2024
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
British journal of haematology · May 1, 2024
MYC overexpression: adding another piece to the puzzle of high-risk mantle cell lymphoma.
Haematologica · Apr 1, 2024
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica · Apr 1, 2024
Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
Leukemia & lymphoma · Feb 1, 2024